
X
AbbVie braces for impact of Humira biosimilars in Europe
https://pharmaphorum.com/news/abbvie-braces-for-impact-of-humira-biosimilars-in-europe/
The European Commission (EC) is proposing to adjust intellectual property (IP) rules to help Europe’s pharma companies tap into fast-growing global markets.
Adrian van den Hoven of Medicines for Europe addresses three big questions facing the biosmilars sector in Europe in 2018.